During the launch of Nicorette® QuickMist at the Kuala Lumpur Nicotine Addiction International Conference (KLNAC) 2023, a panel of distinguished experts led the discussion on the role of Nicotine Replacement Therapy (NRT) on smoking cessation management. The panel comprised of notable experts, including Professor Chris Bullen (New Zealand), Associate Professor Dr Amer Siddiq bin Amer Nordin (Malaysia), Dr Philip Tønnesen (Denmark) and Professor Philip Eng (Singapore).
Patients with immune-mediated inflammatory diseases face increased COVID-19 risks, but mRNA vaccines offer crucial protection against severe outcomes, including hospitalisation and death, as highlighted by real-world data.
Antibiotic misuse and overuse fuel mutations in bacteria, leading to drug-resistant “superbugs,” with terrifying aftermath. Without intervention, antimicrobial resistance could cause 10 million deaths annually by 2050.
Every year, from November 18–24, the World Antimicrobial Awareness Week highlights these risks and promotes innovative treatments, enhanced surveillance, and best-practice sharing among clinicians. This article offers insights on the use of the fixed-dose combination antibiotic ceftazidime-avibactam in daily hospital settings.
The US Centers for Disease Control and Prevention and the Ministry of Health Singapore recommend a third dose of mRNA-1273 or BNT162b2 COVID-19 vaccine as a part of the primary vaccination course in individuals with moderate to severe immunocompromised (IC) conditions. A recent systematic literature review and pairwise meta-analysis comparing the clinical effectiveness of mRNA-1273 versus BNT162b2 in IC individuals found that mRNA-1273 is associated with better clinical outcomes compared with BNT162b2 in the vulnerable IC populations.
Invasive aspergillosis and mucormycosis are two of the most common
mould infections, and a growing problem worldwide, particularly amongst those
who are immunocompromised. Despite recent advances in
the clinical understanding of these mould
infections, the mortality rate can increase significantly if these
infections are left untreated. Therefore, there is a need for early diagnosis
and timely therapeutic intervention. However, diagnosis remains a major
challenge owing to atypical or insidious clinical presentation in patients.
In this symposium, Professor Cornely shares his insights on the diagnosis and
management of invasive aspergillosis and mucormycosis and his recommendations
for optimising patient outcomes, including his preferred evidence-based
COVID-19 vaccination can reduce the risk of long COVID if given before SARS-CoV-2 infection.
Findings suggest that vaccination before infection confers only partial protection in the post-acute phase of the disease. Hence, reliance on vaccination as a sole mitigation strategy may not optimally reduce long-term health consequences of SARS-CoV-2 infection.